Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 29 July

Paulina Peters
July 29, 2021

Morning Bell 28 July

Jessica Amir
July 28, 2021

Morning Bell 27 July

Jessica Amir
July 27, 2021

Morning Bell 26 July

Jessica Amir
July 26, 2021

Weekly Wrap 23 July

Jessica Amir
July 23, 2021

Morning Bell 23 July

Jessica Amir
July 23, 2021

Morning Bell 22 July

Jessica Amir
July 22, 2021

Morning Bell 21 July

Sophia Mavridis
July 21, 2021

Morning Bell 20 July

Paulina Peters
July 20, 2021

Morning Bell 19 July

Jessica Amir
July 19, 2021

Weekly Wrap 16 July

Jessica Amir
July 16, 2021